Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma

Zhang, Haiwen; Hou, Xiaowei; Cai, Huimin; Zhuang, Xun

doi:10.1080/13645706.2017.1286356

Cited by 50 publications

(40 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 weeks after treatment have also been reported. 38,39 RFA is another ablation technique more commonly used to treat intrahepatic HCC. The hypothesis that ablation can cause tumourspecific immune responses was tested on tumour samples and peripheral blood mononuclear cells (PBMCs) collected from patients before and after RFA.…”

Section: Key Pointsmentioning

confidence: 99%

Combined locoregional-immunotherapy for liver cancer

Greten

Mauda-Havakuk

Heinrich

et al. 2019

Journal of Hepatology

161

123

View full text Add to dashboard Cite

Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumour elimination. Immunological ''side effects" have been described in response to locoregional therapies in animal studies and in patients. With the advent of immunotherapy for hepatocellular carcinoma, there is increasing interest in determining the best way to combine immunotherapy with locoregional therapies. Herein, we provide a compact summary of answered and unanswered questions in the field, including: What animal model is best suited to test combined immune-locoregional treatments? How does tumour cell death affect immune responses? What type of immune responses have been observed in patients treated with different types of locoregional therapies? What can be surmised from the results of the first study testing the combination of locoregional therapy with immune checkpoint blockade? Finally, we discuss the outlook for this rapidly growing area of research, focussing on the issues which must be overcome to bridge the gap between interventional radiology and cancer immunology. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Combined locoregional-immunotherapy for liver cancer

Greten

Mauda-Havakuk

Heinrich

et al. 2019

Journal of Hepatology

161

123

View full text Add to dashboard Cite

show abstract

“…In addition, T cells are the primary cell type in tumor immunity; among them, CD4+ subtypes could modulate the anti-tumor immunity via secreting cytokines, while CD8+ subtypes could conduct the secretion of specific inhibitory cytokines, including IFN-γ and TNF-α. CD4+ subtypes, including Th1 and Th2, could not only promote the cytotoxic effect of CTL cells via secreting IL-2, IL-12, IFN-γ, TNF-α, but also stimulate humoral immunity response, promote antibody production and suppress Th1 factors secretion via secreting IL-4, IL-6, IL-8, and IL-10 [30,31]. In the present study, amygdalin treatment (10, 15, and 20 µg/ml) significantly increases the cell growth of T cells derived from peripheral blood of healthy donors and also rescues the cell growth of T cells derived from patients with HBVrelated HCC.…”

Section: Discussionmentioning

confidence: 99%

Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway

Wang

Zhang²,

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection is a high-risk factor of hepatocellular carcinoma (HCC) . Cellular immune responses are essential for HCC development, and the CD4+ and CD8+ T subtypes are identified as the primary anti-tumor immune cells. In the study, we investigated the effect and mechanism of amygdalin in the cellular immune response in HBV-related HCC and HCC progression. Methods: The cell proliferation was examined by MTT analysis. Cells metastasis ability was detected by Invasion and migration assays. Quantification of apoptotic cells was performed with Flow cytometer assay. The protein levels of p-STAT3, STAT3, p-JAK2, JAK2, caspase-3, cleaved caspase-3 were detected by performing immunoblotting assays. Results: We demonstrate that amygdalin treatment could rescue the HBV-T cell viability and IFN-γ and TNF-αproduction . In HBV-T cells, the MFI levels of CD8 + are lower than that in NC-T cells. Moreover, the phosphorylation levels of STAT3 and JAK2 are higher in HBV-T cells, compared to those in NC-T cells, and then reduced by amygdalin treatment. Co-culture with HBV-T cells could reduce IFN-γ and TNF-α, production while increase IL-6 and IL-10 production in HepG2.2.15 cells; these alterations could be partially reversed by amygdalin pretreatment. Finally, co-culture with HBV-T cells significantly promoted the cell viability, inhibited the apoptosis, and promoted the migration of HepG2.2.15 cells , and these alterations could be partially reversed by amygdalin treatment. Conclusion: Our findings provide a rationale for further studies on the functions and mechanism of amygdalin inhibiting HBV-related HCC cell proliferation, invasion, and migration via T cell-mediated tumor immunity.

show abstract

“…In addition, T cells are the primary cell type in tumor immunity; among them, CD4+ subtypes could modulate the antitumor immunity via secreting cytokines, while CD8+ subtypes could conduct the secretion of specific inhibitory cytokines, including IFN-γ and TNF-α. CD4+ subtypes, including Th1 and Th2, could not only promote the cytotoxic effect of CTL cells via secreting IL-2, IL-12, IFN-γ, TNF-α, but also stimulate humoral immunity response, promote antibody production and suppress Th1 factors secretion via secreting IL-4, IL-6, IL-8, and IL-10 [30,31]. In the present study, amygdalin treatment (10, 15, and 20 µg/ml) significantly increases the cell growth of T cells derived from peripheral blood of healthy donors and also rescues the cell growth of T cells derived from patients with HBV-related HCC.…”

Section: Complex T Cell Immune Responses Are Associated With Hbv Infementioning

confidence: 99%

“…It has been proposed that tumors can increase the production of Th2 cytokines, such as IL-4, IL-6, IL-8, and IL-10. IL-4 and IL-10 are negative regulators in the antitumor immune responses, and they can inhibit IL-2, IL-12, IFN-γ, and TNF-α production by Th1 cells [30]. In the serum of patients with hepatocellular carcinoma and supernatants of peripheral monocytes cocultured with Huh7 cells, the levels of cytokines (IL-4, IL-6, and IL-10) could be upregulated, while the level of IFN-γ could be downregulated [17].…”

Section: Complex T Cell Immune Responses Are Associated With Hbv Infementioning

confidence: 99%

Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway

Wang

Zhang²,

Sun

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection is a high-risk factor of hepatocellular carcinoma (HCC). Cellular immune responses are essential for HCC development, and the CD4+ and CD8+ T subtypes are identified as the primary anti-tumor immune cells. In the study, we investigated the effect and mechanism of amygdalin in the cellular immune response in HBV-related HCC and HCC progression.Methods: The cell proliferation was examined by MTT analysis. Cells metastasis ability was detected by Invasion and migration assays. Quantification of apoptotic cells was performed with Flow cytometer assay. The protein levels of p-STAT3, STAT3, p-JAK2, JAK2, caspase-3, cleaved caspase-3 were detected by performing immunoblotting assays.Results: We demonstrate that amygdalin treatment could rescue the HBV-T cell viability and IFN-γ and TNF-αproduction. In HBV-T cells, the MFI levels of CD8+ are lower than that in NC-T cells. Moreover, the phosphorylation levels of STAT3 and JAK2 are higher in HBV-T cells, compared to those in NC-T cells, and then reduced by amygdalin treatment. Co-culture with HBV-T cells could reduce IFN-γ and TNF-α, production while increase IL-6 and IL-10 production in HepG2.2.15 cells; these alterations could be partially reversed by amygdalin pretreatment. Finally, co-culture with HBV-T cells significantly promoted the cell viability, inhibited the apoptosis, and promoted the migration of HepG2.2.15 cells, and these alterations could be partially reversed by amygdalin treatment. Conclusion: Our findings provide a rationale for further studies on the functions and mechanism of amygdalin inhibiting HBV-related HCC cell proliferation, invasion, and migration via T cell-mediated tumor immunity.

show abstract

Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma

Abstract: Microwave ablation could relieve the suppression of immune function caused by tumors, promote the deviation of Th2/Th1, and improve immune dysfunction in patients with hepatocellular carcinoma.

Cited by 50 publications

References 21 publications

Combined locoregional-immunotherapy for liver cancer

Combined locoregional-immunotherapy for liver cancer

Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway

Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway

Contact Info

Product

Resources

About